LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), ...

Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

and Adbry ® (tralokinumab-ldrm) in the treatment of patients 12 years of age or older with moderate to severe atopic dermatitis (AD). The findings are being presented across 18 posters at the ...

It is also approved for adults in the US under the tradename Adbry. Vice president and ... between 12-17 years of age living with atopic dermatitis will now have more treatment options available ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

EADV 2024 Nemolizumab Reassures in Long-Term Atopic Dermatitis Study An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of nemolizumab ...

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

Positive results were announced from the ECZTEND extension study evaluating Adbry ® (tralokinumab ... and older with moderate- to- severe atopic dermatitis (AD) who took part in a previous ...

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin ...

1 Tralokinumab-ldrm is marketed in the U.S. as Adbry for patients 12 years of ... to meet the unique needs of patients living with atopic dermatitis and chronic hand eczema," says Shannon ...